Overview

Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells Specific in NY-ESO-1/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

Status:
Recruiting

Trial end date:
2025-05-30

Target enrollment:

Participant gender:

Summary

This trial will evaluate safety and efficacy of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with non-small cell lung cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab